KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $279.6 million.

  • CRISPR Therapeutics AG's Non-Current Assets fell 830.76% to $279.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 597.61%. This contributed to the annual value of $279.6 million for FY2025, which is 830.76% down from last year.
  • CRISPR Therapeutics AG's Non-Current Assets amounted to $279.6 million in Q4 2025, which was down 830.76% from $316.2 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Non-Current Assets peaked at $420.7 million during Q3 2022, and registered a low of $125.6 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Non-Current Assets had a median value of $320.4 million in 2023 and averaged $316.6 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Non-Current Assets soared by 24428.65% in 2021, and later tumbled by 2244.34% in 2023.
  • CRISPR Therapeutics AG's Non-Current Assets (Quarter) stood at $334.4 million in 2021, then increased by 16.65% to $390.0 million in 2022, then dropped by 17.57% to $321.5 million in 2023, then decreased by 5.16% to $304.9 million in 2024, then decreased by 8.31% to $279.6 million in 2025.
  • Its Non-Current Assets stands at $279.6 million for Q4 2025, versus $316.2 million for Q3 2025 and $296.0 million for Q2 2025.